Overview

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
0
Participant gender:
All
Summary
The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Criteria
Inclusion Criteria:

- Male or Female

- Current diagnosis of Generalized Anxiety Disorder

- Age 18 - 70

Exclusion Criteria:

- Women who are pregnant, or breast-feeding

- Use of illicit drugs

- History of drug or alcohol dependence